KRAS and cancer: The most commonly mutated residues in RAS-driven cancers included Gly12, Gln61, and Gly13, with KRAS mutations at codon 12 being particularly dominant in pancreatic adenocarcinomas (Smit et al., 1988) and other exocrine pancreatic carcinomas (Almoguera et al., 1988).